CA2566677A1 - Therapie combinatoire pour traiter l'infection par le virus de l'hepatite - Google Patents

Therapie combinatoire pour traiter l'infection par le virus de l'hepatite Download PDF

Info

Publication number
CA2566677A1
CA2566677A1 CA002566677A CA2566677A CA2566677A1 CA 2566677 A1 CA2566677 A1 CA 2566677A1 CA 002566677 A CA002566677 A CA 002566677A CA 2566677 A CA2566677 A CA 2566677A CA 2566677 A1 CA2566677 A1 CA 2566677A1
Authority
CA
Canada
Prior art keywords
ifn
alpha
individual
administering
inhibitor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002566677A
Other languages
English (en)
Inventor
Osman N. Ozes
Scott D. Seiwert
Lawrence M. Blatt
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Intermune Inc
Original Assignee
Intermune, Inc.
Osman N. Ozes
Scott D. Seiwert
Lawrence M. Blatt
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Intermune, Inc., Osman N. Ozes, Scott D. Seiwert, Lawrence M. Blatt filed Critical Intermune, Inc.
Publication of CA2566677A1 publication Critical patent/CA2566677A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA002566677A 2004-05-13 2005-05-09 Therapie combinatoire pour traiter l'infection par le virus de l'hepatite Abandoned CA2566677A1 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US57122704P 2004-05-13 2004-05-13
US57119604P 2004-05-13 2004-05-13
US60/571,196 2004-05-13
US60/571,227 2004-05-13
PCT/US2005/016353 WO2005110455A2 (fr) 2004-05-13 2005-05-09 Therapie combinatoire pour traiter l'infection par le virus de l'hepatite

Publications (1)

Publication Number Publication Date
CA2566677A1 true CA2566677A1 (fr) 2005-11-24

Family

ID=35394669

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002566677A Abandoned CA2566677A1 (fr) 2004-05-13 2005-05-09 Therapie combinatoire pour traiter l'infection par le virus de l'hepatite

Country Status (2)

Country Link
CA (1) CA2566677A1 (fr)
WO (1) WO2005110455A2 (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7597884B2 (en) * 2004-08-09 2009-10-06 Alios Biopharma, Inc. Hyperglycosylated polypeptide variants and methods of use
EP2680859B1 (fr) 2011-03-02 2022-04-27 Jerome Schentag Compositions, méthodes de traitement et diagnostics dans le traitement de la stéatose hépatique seule ou en association avec une infection par le virus de l'hépatite c
WO2013024157A2 (fr) * 2011-08-17 2013-02-21 INSERM (Institut National de la Santé et de la Recherche Médicale) Combinaisons d'agents ciblant un hôte pour le traitement et la prévention d'une infection par le vhc
PT3122757T (pt) 2014-02-28 2023-11-03 Hangzhou Dac Biotech Co Ltd Ligantes carregados e as suas utilizações em conjugação
SG10202110259QA (en) 2017-10-05 2021-10-28 Fulcrum Therapeutics Inc Use of p38 inhibitors to reduce expression of dux4
US10342786B2 (en) 2017-10-05 2019-07-09 Fulcrum Therapeutics, Inc. P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD
WO2020132409A1 (fr) * 2018-12-20 2020-06-25 Trustees Of Boston University Inhibiteurs de stk19 pour le traitement du cancer

Also Published As

Publication number Publication date
WO2005110455A2 (fr) 2005-11-24
WO2005110455A3 (fr) 2007-12-21

Similar Documents

Publication Publication Date Title
WO2006016930A2 (fr) Procédés de traitement de l’infection vhc
US7597884B2 (en) Hyperglycosylated polypeptide variants and methods of use
US7407973B2 (en) Use of pirfenidone in therapeutic regimens
US20100099851A1 (en) Synthetic hyperglycosylated, protease-resistant polypeptide variants, oral formulations and methods of using the same
US20090226400A1 (en) Continuous delivery methods for treating hepatitis virus infection
US20070258946A1 (en) Combination Therapy for Treating Hepatitis C Virus Infection
KR20120110090A (ko) Ｃ형 간염 바이러스 복제의 신규한 마크로시클릭 저해제
CA2566677A1 (fr) Therapie combinatoire pour traiter l'infection par le virus de l'hepatite
US7932267B2 (en) Use of α-glucosidase inhibitors to treat alphavirus infections
WO2005110478A2 (fr) Polytherapie destinee a traiter des troubles fibreux
WO2005067963A1 (fr) Utilisation d'un interferon modifie par du polyethylene glycol dans des schemas posologiques de dosage therapeutique
WO2004078193A1 (fr) Therapie medicamenteuse a base d'interferon pour le traitement de maladies virales et de la fibrose hepatique
WO2005062949A2 (fr) Methode permettant de traiter l'infection par un hepatovirus
WO2005038056A1 (fr) Polytherapie pour le traitement de maladies virales
WO2013024158A1 (fr) Combinaisons d'inhibiteurs de protéine kinase et d'interférons ou d'inhibiteurs de protéine kinase et d'antiviraux agissant directement pour le traitement et la prévention d'une infection par le vhc
WO2004105684A2 (fr) Therapie combinatoire pour traiter des troubles chroniques
RU2392963C2 (ru) Синтетические варианты гипергликозилированного протеазо-резистентного полипептида, пероральные композиции и способы применения таких вариантов
EP1596883A1 (fr) Therapie de medicament interferon pour le traitement de maladies virales et hepatiques
WO2005039598A1 (fr) Procede de traitement des maladies alcooliques du foie
CN101102787A (zh) 合成的超糖基化、抗蛋白酶的多肽变体、口服制剂及其使用方法
CN101516389A (zh) 用于治疗病毒感染的联合治疗

Legal Events

Date Code Title Description
FZDE Discontinued